Related Experiment Video

Updated: Jun 8, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer

Ayako Sanui1, Fusanori Yotsumoto, Hiroshi Tsujioka

  • 1Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.

Anticancer Research
|September 28, 2010
PubMed

Insights

Targeting heparin-binding epidermal growth factor-like growth factor (HB-EGF) with CRM197 shows promise for advanced gastric cancer (GC) therapy. Combining CRM197 with other agents significantly enhances antitumor effects and apoptosis in GC cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Advanced gastric cancer (GC) presents a significant clinical challenge with poor prognosis despite available treatments.
  • Development of targeted therapies is crucial for improving outcomes in GC patients.
  • Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is implicated in cancer progression.

Purpose of the Study:

  • To evaluate the expression of epidermal growth factor receptor (EGFR) ligands in GC.
  • To assess the therapeutic potential of the HB-EGF inhibitor CRM197 in GC.
  • To investigate the combined effects of CRM197 with other anticancer agents.

Main Methods:

  • Analysis of EGFR ligand expression in GC cell lines.
  • Treatment of GC cells with CRM197 as a single agent and in combination therapy.
  • Assessment of cell apoptosis and antitumor effects.

Main Results:

  • HB-EGF was identified as the predominant EGFR ligand in GC cells.
  • CRM197 treatment induced significant apoptosis in GC cells.
  • Combination therapy with CRM197 and other anticancer agents, including paclitaxel, enhanced apoptosis and demonstrated synergistic antitumor effects.

Conclusions:

  • HB-EGF represents a rational therapeutic target for advanced gastric cancer.
  • CRM197, an HB-EGF inhibitor, exhibits potential as a single agent and in combination therapies for GC.
  • Combination strategies involving CRM197 may improve treatment efficacy for gastric cancer.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...